On December 2, 2024, Rekha Hemrajani, a Director at ALX Oncology Holdings Inc (ALXO, Financial), purchased 30,000 shares of the company. Following this transaction, the insider now owns a total of 33,000 shares. The purchase was documented in a SEC Filing.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway. The company aims to enhance the immune system's ability to destroy cancer cells.
The insider's recent acquisition of shares is part of a broader trend within the company. Over the past year, there have been four insider buys and fourteen insider sells. This indicates a mixed sentiment among insiders regarding the company's future prospects.
Shares of ALX Oncology Holdings Inc were trading at $1.55 each on the day of the purchase, resulting in a market cap of $82.28 million. The company's valuation metrics, such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, provide further insights into the stock's current market position.
The insider's activity, as well as the overall insider transaction history, can be a valuable indicator for investors considering the stock's potential.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
